DexCom (NASDAQ:DXCM) Price Target Cut to $75.00 by Analysts at TD Cowen

Posted by Latisha Jones on May 1st, 2026

DexCom (NASDAQ:DXCM – Get Free Report) had its target price dropped by equities research analysts at TD Cowen from $84.00 to $75.00 in a research report issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the medical device company’s stock. TD Cowen’s price objective would indicate a potential upside of 22.74% from the stock’s previous close.

A number of other equities research analysts have also issued reports on the company. Barclays set a $67.00 price target on DexCom and gave the company an “underweight” rating in a research report on Friday. Citigroup increased their price target on DexCom from $77.00 to $84.00 and gave the company a “buy” rating in a research report on Wednesday, March 11th. Piper Sandler reaffirmed an “overweight” rating on shares of DexCom in a research report on Thursday, February 5th. Wells Fargo & Company reduced their price target on DexCom from $93.00 to $85.00 and set an “overweight” rating on the stock in a research report on Friday, February 13th. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of DexCom in a research report on Monday, January 12th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $83.73.

View Our Latest Research Report on DXCM

DexCom Trading Up 2.6%

DXCM traded up $1.55 during mid-day trading on Friday, hitting $61.10. 7,990,597 shares of the stock were exchanged, compared to its average volume of 4,896,271. The firm’s fifty day moving average is $65.87 and its two-hundred day moving average is $66.40. DexCom has a 1-year low of $54.11 and a 1-year high of $89.98. The company has a current ratio of 1.88, a quick ratio of 1.59 and a debt-to-equity ratio of 0.45. The company has a market cap of $23.58 billion, a PE ratio of 29.10, a PEG ratio of 1.12 and a beta of 1.55.

DexCom (NASDAQ:DXCM – Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. The company had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. DexCom had a return on equity of 32.12% and a net margin of 17.94%.DexCom’s revenue for the quarter was up 15.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.32 EPS. Equities analysts forecast that DexCom will post 2.49 earnings per share for the current fiscal year.

Insider Buying and Selling at DexCom

In other news, EVP Michael Jon Brown sold 1,700 shares of the firm’s stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $63.04, for a total transaction of $107,168.00. Following the sale, the executive vice president owned 111,204 shares of the company’s stock, valued at approximately $7,010,300.16. This trade represents a 1.51% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.32% of the company’s stock.

Institutional Investors Weigh In On DexCom

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its position in shares of DexCom by 2.3% during the 3rd quarter. Vanguard Group Inc. now owns 49,456,043 shares of the medical device company’s stock worth $3,327,897,000 after acquiring an additional 1,133,638 shares in the last quarter. Geode Capital Management LLC raised its position in shares of DexCom by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 11,006,183 shares of the medical device company’s stock worth $727,842,000 after acquiring an additional 42,411 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in DexCom by 6.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,999,057 shares of the medical device company’s stock worth $530,897,000 after buying an additional 516,526 shares during the period. Norges Bank acquired a new position in DexCom during the fourth quarter worth approximately $483,356,000. Finally, Invesco Ltd. increased its position in DexCom by 14.8% during the fourth quarter. Invesco Ltd. now owns 5,315,367 shares of the medical device company’s stock worth $352,781,000 after buying an additional 686,228 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom News Summary

Here are the key news stories impacting DexCom this week:

Positive Sentiment: Q1 beat on both EPS and revenue, with revenue up ~15% YoY and non‑GAAP EPS of $0.56 beating estimates; margins expanded, driving the bullish near‑term reaction. DexCom Stock Up on Q1 Earnings & Revenues Beat, Margins Rise
Positive Sentiment: Analysts remain constructive: BTIG reaffirmed a Buy rating (cut PT modestly), and broker consensus price targets (~$86.50) sit well above the current share price, supporting upside potential. BTIG Remains Bullish on DexCom, Inc. (DXCM)
Positive Sentiment: Management highlighted strong international demand and product launches as growth drivers and provided a profitability outlook that investors interpreted as improving operating leverage. DexCom Inc (DXCM) Q1 2026 Earnings Call Highlights
Neutral Sentiment: Company reaffirmed its FY26 revenue forecast (roughly $5.2–5.3B), meaning management did not raise guidance despite the beat; this is neutral-to-mixed since it signals caution while keeping expectations in line. Dexcom reaffirms full-year forecast after topping quarterly estimates
Neutral Sentiment: Full earnings materials and transcripts are available for deeper scrutiny (useful for investors wanting management color on US vs. international trends and product cadence). Investor Slide Deck / Press Release
Negative Sentiment: Management cited the “current geopolitical environment” as a reason for not raising FY26 revenue guidance, which injected caution and helped trigger an after‑hours selloff despite the beat. Dexcom reports 15% YoY revenue uptick in Q1 yet maintains prior FY26 outlook
Negative Sentiment: Some market reports noted an immediate post‑earnings decline as investors focused on guidance conservatism rather than the beat—an indicator of how forward guidance, not just current results, is driving stock moves. Dexcom falls over 5% despite better‑than‑expected Q1 print, as revenue guidance disappoints

DexCom Company Profile

(Get Free Report)

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.